ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
Employee Vinayak Sawant sold 1,100 shares of Rubicon Research Ltd worth ₹0.20 Crore. This disclosure is a routine regulatory filing under PIT regulations.
Promoter General Atlantic Singapore RR Pte Ltd sold equity shares in market transactions aggregating to Rs. 232.50 Crore across two tranches.
Promoter General Atlantic Singapore RR Pte. Ltd. sold 1,40,00,000 shares (8.45% stake) of Rubicon Research Ltd via on-market sales on August 25 and 26, 2026.
Rubicon Research Ltd held its 27th Annual General Meeting on August 26, 2026. The meeting covered adoption of financial statements, dividend declaration, and other business.
Rubicon Research Ltd filed a PIT disclosure regarding the sale of equity shares by an employee, Sanjay Renapurkar, totaling ₹1.06 Crore. This is a routine regulatory reporting event.
Rubicon Research reported a strong Q1 FY27 with revenue growing 51% YoY to ₹534 Cr and PAT surging over 95% to ₹85 Cr.
Rubicon Research delivers stellar Q1FY27 results with a 51% revenue jump and 100%+ PAT growth, largely fueled by strong US specialty sales and successful inorganic integration.
Rubicon Research Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Initial Public Offering.
Rubicon Research announced the appointment of Mr. Rohit Saraogi as CFO-Designate, while current CFO Mr. Nitin Jajodia will transition to Chief Commercial Officer. Mr. Venkat Changavalli's term as Chairman was extended.
Rubicon Research reported stellar Q1FY27 results with 51.6% YoY revenue growth. Management revised Operating EBITDA margin guidance upwards to at least 23% for FY27.
Rubicon Research Ltd reported revenue from operations of ₹534.3 Cr (+51.6% YoY) and net profit of ₹84.8 Cr (+95.8% YoY) for Q1 FY27.
Rubicon Research issued a corrigendum to its FY 2025-26 Integrated Annual Report to correct typographical errors in the MD&A and Shareholding Pattern. The revised report is available.
Rubicon Research scheduled a board meeting for August 14, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Rubicon Research Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, in compliance with SEBI Listing Regulations.
Rubicon Research Ltd has issued the notice for its 27th Annual General Meeting, along with the Integrated Annual Report for FY 2025-26.
Rubicon Research Limited announced the proposed merger of its wholly-owned subsidiary, Kia Health Tech Private Limited, into the company, seeking regulatory exemption under SEBI circulars.
Rubicon Research Limited's subsidiary acquired a manufacturing facility in New Jersey, USA, from InvaTech Pharma Solutions, LLC for an enterprise value of ₹27.84 Crore.
Rubicon Research announced the date for its 27th AGM and the record date for its final dividend. It also updated the merger of a subsidiary.
Rubicon Research Limited has allotted 1,49,158 equity shares under its Employee Stock Option Scheme 2022. This issuance increases the company's paid-up share capital.
Rubicon Research Ltd has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI Regulation 31. The report reflects recent ESOP allotment data.
Rubicon Research disclosed a US FDA inspection at its Pithampur facility, yielding 2 procedural observations. The company is confident in resolving them, with no impact on data integrity or operations.
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.
Rubicon Research delivered a strong Q4 FY26 with 44% revenue growth and 112% profit increase, driven by a robust product pipeline and stable pricing despite outsourcing manufacturing for excess demand.
Rubicon Research recommended a final dividend of ₹1.5 per equity share for FY2026. The record date and AGM schedule will be announced following future board approval.
Rubicon Research Limited filed its Annual Secretarial Compliance Report for the financial year 2026. The report confirms full compliance with SEBI regulations with no fines levied.
Rubicon Research extended the timeline for utilising ₹147.63 Crore in unutilised IPO proceeds until March 2027. This extension provides operational flexibility for strategic investments and debt repayment.
Rubicon Research approved a new Employee Stock Option Scheme 2026 covering 24,84,415 equity shares. The plan aims to incentivize employees across the company and its subsidiaries.
Rubicon Research (Q4 FY26) reported revenue of ₹5,139M (up 43.5% YoY) and PAT of ₹768M (up 111.8% YoY). Strategy focuses on specialty products and US nasal spray market leadership.
Rubicon Research Ltd reported revenue from operations of ₹513.9 Cr (+43.5% YoY) and net profit of ₹76.8 Cr (+112.2% YoY) for Q4 FY26.